Market Cap 2.09B
Revenue (ttm) 0.00
Net Income (ttm) -422.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,113,300
Avg Vol 1,448,318
Day's Range N/A - N/A
Shares Out 145.28M
Stochastic %K 53%
Beta 1.32
Analysts Strong Sell
Price Target $33.47

Company Profile

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Synd...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 866 8547
Address:
161 Oyster Point Boulevard, South San Francisco, United States
NextBigRun
NextBigRun Jun. 20 at 2:43 AM
GLMD is the definition of asymmetric. No debt. Under cash. Biotech catalysts incoming. Float already pushed it to $2.08 on air imagine what happens with real news behind it. $ARWR $NBSE $SANA $DNLI
0 · Reply
Winning_calls
Winning_calls Jun. 11 at 4:59 PM
$DNLI 😉🤞🤞
0 · Reply
swingingtech
swingingtech Jun. 9 at 1:25 PM
$VB $DNLI $AZTA $VMEO https://wallstreetwaves.com/analysts-project-vb-to-reach-270/
0 · Reply
Winning_calls
Winning_calls Jun. 9 at 3:41 AM
$DNLI pick me up @ $15.15
0 · Reply
BobBijawklah
BobBijawklah Jun. 6 at 3:17 PM
$ACAD couple good stocks for everyone to research and see if it makes a good investmetn for me these work. $DNLI Denali theraputics . First listen to ryan watts and look at his education and mannerisms a true leader. they have a submission to fda for hunters disease no cure 100% mortality rate. $RCKT two drugs out for approval to fda one has a manufacturing crl but again they are all ultra orphan rare diseease with no standard of care of an ineffective standard of care. The stock dropped due to a patient death in another late stage trial. Death happened because they added a conditioning agent to several patients who were enrolled . A rare side effect of that conditioning agent is capilary leak syndrome. So i am confident the fda releases the hold when they update and remove that conditioning agent from the pre treatment protocol. I am more confident and comfortable with denali than rocket because of RFK jr and his reluctance to endorse expensive genetic modifying drugs.
0 · Reply
TimRegan_WTR
TimRegan_WTR May. 29 at 5:50 PM
0 · Reply
research_WTR
research_WTR May. 29 at 5:42 PM
TREM2 Agonists: A New Frontier in Neurodegeneration Despite past clinical setbacks, Sanofi’s $470$600M acquisition of Vigil Neuroscience signals renewed confidence in TREM2 as a key neuroinflammation target in Alzheimer’s and other disorders. 🔹 TREM2 helps microglia clear toxic proteins and regulate inflammation in the CNS 🔹 Past mAb candidates (ALEC/ABBV, DNLI) failed in trials due to lack of efficacy or safety concerns 🔹 Vigil’s oral TREM2 agonist (VG-3927) showed strong Phase 1 data and heads to Phase 2 in 2H25 🔹 Sanofi’s support may reshape the future of microglia-targeted neurotherapies Subscribe at our website to follow along with Robert Sassoon! $ALEC $ABBV $DNLI $TAK $NVS
0 · Reply
Carl_K
Carl_K May. 22 at 4:53 AM
$SNY $VIGL $INMB $ALEC $DNLI Sanofi - Vigil buyout, ~400% premium, TREM2 / microglia modulation for AD, VG-3927 is Phase 2-ready, $470 million deal. Microglia and brain immune cell modulation are the important targets here. Cfr. my blog on them from 2022. If not mistaken, TREM2 is a target that's failed to show substantial impact so far. Alector and Denali (listed as competitors in INmune's 10K) were leaders in that regard. Difficulty: you're manipulating cells with very complex behaviors (microglia) simply because TREM2 appears implicated in CNS diseases. https://www.thetyp.com/post/the-10-billion-unicorn-in-inmune-bio-it-s-the-micro-glia-stupid
3 · Reply
JarvisFlow
JarvisFlow May. 19 at 5:57 PM
B of A Securities has adjusted their stance on Denali Therapeutics ( $DNLI ), setting the rating to Buy with a target price of 28 → 27.
0 · Reply
BioTechHealthX
BioTechHealthX May. 11 at 3:53 AM
$DNLI With new manufacturing facilities, & major partnerships, Denali Therapeutics is positioned for rapid growth. https://biotechhealthx.com/biotech-news/denali-therapeutics-the-future-of-neuroscience-innovation/
0 · Reply
Latest News on DNLI
Denali Therapeutics: Vast Pipeline, First Approval Up Ahead

Mar 20, 2025, 2:16 PM EDT - 3 months ago

Denali Therapeutics: Vast Pipeline, First Approval Up Ahead


Why Is Denali Therapeutics Stock Trading Higher On Wednesday?

Jan 15, 2025, 2:26 PM EST - 5 months ago

Why Is Denali Therapeutics Stock Trading Higher On Wednesday?


Denali Therapeutics ALS drug fails in mid-stage trial

Jan 6, 2025, 4:43 PM EST - 6 months ago

Denali Therapeutics ALS drug fails in mid-stage trial


Denali Has A Neurodegenerative Edge Despite Market Skepticism

Nov 16, 2024, 8:56 AM EST - 7 months ago

Denali Has A Neurodegenerative Edge Despite Market Skepticism


Denali's New Summit: Changing Hunter Syndrome Landscape

Oct 2, 2023, 5:26 AM EDT - 1 year ago

Denali's New Summit: Changing Hunter Syndrome Landscape


MPS II And Beyond: Implications Of Denali's Promising Pipeline

Jul 23, 2023, 12:51 AM EDT - 2 years ago

MPS II And Beyond: Implications Of Denali's Promising Pipeline


Denali: Need Patient Data To Justify That High Valuation

Jan 16, 2023, 12:15 PM EST - 2 years ago

Denali: Need Patient Data To Justify That High Valuation


7 Best Small-Cap Stocks to Buy for 2022 and Beyond

Dec 21, 2022, 10:55 AM EST - 2 years ago

7 Best Small-Cap Stocks to Buy for 2022 and Beyond

ARVN AXSM FATE GTLS RCKT


NextBigRun
NextBigRun Jun. 20 at 2:43 AM
GLMD is the definition of asymmetric. No debt. Under cash. Biotech catalysts incoming. Float already pushed it to $2.08 on air imagine what happens with real news behind it. $ARWR $NBSE $SANA $DNLI
0 · Reply
Winning_calls
Winning_calls Jun. 11 at 4:59 PM
$DNLI 😉🤞🤞
0 · Reply
swingingtech
swingingtech Jun. 9 at 1:25 PM
$VB $DNLI $AZTA $VMEO https://wallstreetwaves.com/analysts-project-vb-to-reach-270/
0 · Reply
Winning_calls
Winning_calls Jun. 9 at 3:41 AM
$DNLI pick me up @ $15.15
0 · Reply
BobBijawklah
BobBijawklah Jun. 6 at 3:17 PM
$ACAD couple good stocks for everyone to research and see if it makes a good investmetn for me these work. $DNLI Denali theraputics . First listen to ryan watts and look at his education and mannerisms a true leader. they have a submission to fda for hunters disease no cure 100% mortality rate. $RCKT two drugs out for approval to fda one has a manufacturing crl but again they are all ultra orphan rare diseease with no standard of care of an ineffective standard of care. The stock dropped due to a patient death in another late stage trial. Death happened because they added a conditioning agent to several patients who were enrolled . A rare side effect of that conditioning agent is capilary leak syndrome. So i am confident the fda releases the hold when they update and remove that conditioning agent from the pre treatment protocol. I am more confident and comfortable with denali than rocket because of RFK jr and his reluctance to endorse expensive genetic modifying drugs.
0 · Reply
TimRegan_WTR
TimRegan_WTR May. 29 at 5:50 PM
0 · Reply
research_WTR
research_WTR May. 29 at 5:42 PM
TREM2 Agonists: A New Frontier in Neurodegeneration Despite past clinical setbacks, Sanofi’s $470$600M acquisition of Vigil Neuroscience signals renewed confidence in TREM2 as a key neuroinflammation target in Alzheimer’s and other disorders. 🔹 TREM2 helps microglia clear toxic proteins and regulate inflammation in the CNS 🔹 Past mAb candidates (ALEC/ABBV, DNLI) failed in trials due to lack of efficacy or safety concerns 🔹 Vigil’s oral TREM2 agonist (VG-3927) showed strong Phase 1 data and heads to Phase 2 in 2H25 🔹 Sanofi’s support may reshape the future of microglia-targeted neurotherapies Subscribe at our website to follow along with Robert Sassoon! $ALEC $ABBV $DNLI $TAK $NVS
0 · Reply
Carl_K
Carl_K May. 22 at 4:53 AM
$SNY $VIGL $INMB $ALEC $DNLI Sanofi - Vigil buyout, ~400% premium, TREM2 / microglia modulation for AD, VG-3927 is Phase 2-ready, $470 million deal. Microglia and brain immune cell modulation are the important targets here. Cfr. my blog on them from 2022. If not mistaken, TREM2 is a target that's failed to show substantial impact so far. Alector and Denali (listed as competitors in INmune's 10K) were leaders in that regard. Difficulty: you're manipulating cells with very complex behaviors (microglia) simply because TREM2 appears implicated in CNS diseases. https://www.thetyp.com/post/the-10-billion-unicorn-in-inmune-bio-it-s-the-micro-glia-stupid
3 · Reply
JarvisFlow
JarvisFlow May. 19 at 5:57 PM
B of A Securities has adjusted their stance on Denali Therapeutics ( $DNLI ), setting the rating to Buy with a target price of 28 → 27.
0 · Reply
BioTechHealthX
BioTechHealthX May. 11 at 3:53 AM
$DNLI With new manufacturing facilities, & major partnerships, Denali Therapeutics is positioned for rapid growth. https://biotechhealthx.com/biotech-news/denali-therapeutics-the-future-of-neuroscience-innovation/
0 · Reply
JarvisFlow
JarvisFlow May. 8 at 1:00 PM
Baird has updated their rating for Denali Therapeutics ( $DNLI ) to Outperform with a price target of 29.
0 · Reply
ZacksResearch
ZacksResearch May. 7 at 5:21 PM
$DNLI just reported a wider-than-expected loss — is the pipeline enough to turn things around? 🔍 💸 Q1 loss of 78 cents per share vs. Zacks Consensus Estimate of 71 cents 🚫 No collaboration revenues this quarter. 🚀 BLA for tividenofusp alfa submitted under FDA’s accelerated approval pathway Cash reserves of $1.05 billion give room to maneuver! Is this the moment to buy into potential? Discover the full analysis here 👉 https://www.zacks.com/commentary/2464381/denali-q1-loss-wider-than-expected-hunter-syndrome-drug-in-focus?cid=sm-stocktwits-2-2464381-body&ADID=SYND_STOCKTWITS_TWEET_2_2464381_BODY
0 · Reply
JarvisFlow
JarvisFlow May. 7 at 1:38 PM
HC Wainwright & Co. has adjusted their stance on Denali Therapeutics ( $DNLI ), setting the rating to Buy with a target price of 80 → 32.
0 · Reply
Estimize
Estimize May. 6 at 8:25 PM
$DNLI reported -0.78 EPS and 0.00 revenue for Q1. http://www.estimize.com/intro/dnli?chart=historical&metric_name=eps&utm_content=DNLI&utm_
0 · Reply
Armonica423
Armonica423 May. 6 at 2:13 PM
$DNLI CYDY
0 · Reply
BobBijawklah
BobBijawklah Apr. 23 at 2:22 PM
$DNLI ryan watts is a beast of a CEO . Good things to come expect updates on approval at the shareholders meeting in june.
0 · Reply
Babybillysbiblebonker
Babybillysbiblebonker Apr. 7 at 8:55 PM
$SGMO $LLY decision to partner with $SGMO, rather than other companies ( $VYGR $DNLI) working on blood-brain barrier (BBB) crossing technologies, represents a significant endorsement of Sangamo's capabilities. This choice speaks volumes about Lilly's confidence in Sangamo's expertise and the potential of their approach, which stands out among the various players in this competitive field.
0 · Reply
Babybillysbiblebonker
Babybillysbiblebonker Apr. 4 at 4:44 PM
$SGMO $LLY decision to partner with $SGMO, rather than other companies ( $VYGR $DNLI) working on blood-brain barrier (BBB) crossing technologies, represents a significant endorsement of Sangamo's capabilities. This choice speaks volumes about Lilly's confidence in Sangamo's expertise and the potential of their approach, which stands out among the various players in this competitive field.
0 · Reply
ALDX_Bull
ALDX_Bull Apr. 4 at 4:39 PM
$DNLI Market might affect bios who need to raise cash. Not the case here. Also, Denali production in the US and pharma prices not affected by Tarriffs anyway. MPS market alone for DNLI is multi billions. 5 bagger in 2-3 years. Imagine if LRRK2 hits end of this year. No brainer.
0 · Reply
DoctrBenway
DoctrBenway Apr. 4 at 3:04 PM
$DNLI Fortunate to add 12% @ 11.5.
0 · Reply
BobBijawklah
BobBijawklah Apr. 2 at 6:20 PM
$DNLI back to mid twenties within 6 months once they announce BLA acceptance.
0 · Reply
Photocasion
Photocasion Apr. 2 at 5:40 PM
$DNLI Remember that greenspike? Bigger volume than most of the day combined, seconds before close. Obviously something was preparing
0 · Reply